5.2 Ultrasound-Enhancing Agents and LV Opacification
Key Takeaways
- Commercial UEAs traverse the pulmonary circulation to opacify the LV and improve endocardial-border definition; they are not agitated-saline shunt contrast.
- UEA enhancement is recommended when two or more contiguous LV segments remain inadequately seen for function or regional wall-motion analysis.
- Screen and administer by the selected product's current label, authorized scope, and local protocol, with emergency readiness for uncommon serious reactions.
- Low-MI contrast-specific imaging, coordinated delivery, and correction of attenuation or destruction produce diagnostic borders without excessive microbubble concentration.
Commercial UEAs cross the pulmonary circulation
An injectable ultrasound-enhancing agent, or UEA, contains gas-filled microspheres designed to survive pulmonary transit and enhance the blood pool. In echocardiography, commercial UEAs are used with contrast-specific imaging to opacify the left ventricular cavity and delineate the endocardial border. They are not radiographic iodinated dye, and they are not the hand-agitated saline-air mixture used primarily to test right-to-left shunting. The products have different shells, gases, preparation steps, doses, ingredients, and labels; never treat UEA as one interchangeable drug.
ASE recommends UEA use in a routine resting study when two or more contiguous LV segments cannot be adequately visualized for assessment of ejection fraction or regional wall motion. UEA can also improve reproducibility of LV volumes and function when accurate quantification is clinically important and can help define apical morphology, aneurysm, or suspected thrombus within an appropriate protocol. It cannot create an acoustic window when the heart is not reachable because lung or chest anatomy blocks transmission. Acquire optimized native images first, then identify the specific unanswered question.
| Phase | Essential actions | Frequent failure |
|---|---|---|
| Before administration | Verify patient, order or protocol, indication, agent, current label, hypersensitivity history, IV patency, authority, and emergency readiness | Calling all contrast allergies equivalent or relying on an old blanket contraindication list |
| Initial imaging | Save native loops, activate the system's UEA or low-MI preset, minimize unnecessary depth and sector width | Using ordinary high-MI harmonic imaging that destroys microspheres |
| Delivery | Prepare and administer the exact agent by its label and local policy; coordinate injection or infusion with imaging | Improvising dose, flush, route, or vial handling from another product |
| Optimization | Seek uniform cavity opacification and a crisp border without near-field destruction or basal attenuation | Adding more agent whenever the image is poor, even when concentration is already excessive |
| After administration | Monitor as the label and policy require, recognize symptoms, document dose and response, and discard materials correctly | Leaving before a reaction is assessed or failing to record the administered product |
Safety language must stay current and agent specific
Known or suspected hypersensitivity to the selected microsphere or its components is a central contraindication in current U.S. labels. Some lipid products contain polyethylene glycol, while an albumin-shelled product has different allergy considerations. Ask about the ingredients relevant to the agent being used, not simply shellfish or iodine. Current labels warn that serious cardiopulmonary or hypersensitivity reactions can occur, commonly during or soon after administration, so trained personnel and resuscitation equipment must be available and the patient monitored according to the label and facility policy.
Do not repeat obsolete rules. ASE's 2018 update states that pulmonary hypertension and right-to-left shunts are not blanket contraindications to all UEAs. Current labels instead require product-specific assessment and may warn about systemic embolization when microspheres bypass lung filtration. UEAs are intravenous agents and must not be injected into an arterial line. Pregnancy, pediatrics, sickle cell disease, unstable cardiopulmonary conditions, and other special populations require the current selected-agent label and local medical decision; one product's precaution cannot be generalized to every agent.
Administration by a sonographer depends on education, competency, licensure, authorized scope, and institutional policy. Verify a functioning venous route and never assume an unlabeled catheter is venous. Follow required independent checks and aseptic technique. Explain that the agent improves the ultrasound image and ask the patient to report dyspnea, throat tightness, rash, flushing, chest or back pain, dizziness, or other new symptoms. If a reaction is suspected, stop administration, assess the patient, call for help, initiate the emergency protocol within training, preserve vital information, and document objectively. Do not diagnose the reaction casually or continue imaging merely to finish the protocol.
Optimize the microbubble image
Contrast-specific very-low-mechanical-index imaging preserves microspheres while suppressing tissue signal. Start with the manufacturer's cardiac LVO preset and adjust depth, focus, frequency, gain, and dynamic range for the patient. Save nonforeshortened A4C, A2C, and apical long-axis loops with complete borders. Verify automated tracings against the enhanced blood-tissue interface; papillary muscles and trabeculations follow the same chamber-tracing convention used in native images.
Too high a microsphere concentration causes basal attenuation and shadowing, hiding the very border the agent should reveal. A forceful bolus may create apical swirling or near-field destruction. Correct the delivery and imaging interaction: pause for concentration to fall, use the label-supported slower flush or infusion strategy, lower destructive output, or adjust the protocol. Do not increase gain until noise becomes a false endocardium. A brief high-MI flash may be used under an approved protocol to clear microspheres, followed by low-MI replenishment imaging; continuous high output destroys contrast and current labels warn about arrhythmia risk at high MI.
The endpoint is diagnostic information, not maximum brightness. The cavity should fill homogeneously, myocardium should remain distinguishable, the apex should be visible without foreshortening, and basal segments should not disappear behind attenuation. If a suspected apical thrombus remains, use multiple views and observe whether the filling defect persists against an opacified cavity; near-field artifact, trabeculation, and poor mixing can mimic a mass. The sonographer documents appearance and limitations for physician interpretation rather than declaring thrombus or excluding it from one imperfect loop.
Commercial UEA and agitated saline can both look like bubbles on a monitor, but their destinations answer different questions. UEA intentionally traverses the lungs to enhance the left heart. Agitated saline should densely opacify the right heart and ordinarily be filtered by normal pulmonary capillaries; left-heart appearance is analyzed for a shunt. Selecting the wrong method can produce a technically successful injection that cannot answer the indication.
Read the selected-agent label
Contraindications, ingredients, preparation, dose, route, monitoring, and special-population warnings are product specific and change over time. Current institutional policy and the live prescribing information control.
Despite optimized native imaging, three contiguous apical LV segments remain inadequately visualized in a study requiring accurate ejection fraction and regional wall-motion assessment. What is the best next step?
Which three actions belong in a safe pre-administration check for a commercial UEA? Select three correct responses.
Select all that apply